This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Cadonilimab
Monoclonal antibody
Type
?
Clinical data
Other names
AK104; AK-104
Legal status
Legal status
Investigational
Identifiers
CAS Number
2394841-59-7
UNII
6FYG1DS4NW
Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody[1][2] developed to treat a variety of solid cancer types. In June 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".[3]
Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody developed to treat a variety of solid cancer types. In June 2022 it was approved in China...